PREMAPESSAIRE: Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor

Sponsor
Centre Hospitalier Universitaire de Saint Etienne (Other)
Overall Status
Recruiting
CT.gov ID
NCT02484820
Collaborator
(none)
154
1
2
87
1.8

Study Details

Study Description

Brief Summary

In France, threatened preterm labour concerns 6.5% of pregnancies and is associated with a premature birth in 25.4% of cases.

After 48 hours effective tocolysis, patients do not receive any further treatment while their risk of premature birth has risen from 6.5% to 25%.

A pessary is a silicone ring encircling the cervix. It was initially used as medical treatment of genital prolapse but studies were also conducted for pregnant women in 2 high-risk premature birth situations: cervical incompetence and twin pregnancies.

The multicenter PECEP trial conducted by Goya and al. in asymptomatic short cervix patients between 18 and 22 weeks of gestation showed a significant reduction of premature birth before 34 and 37 weeks of gestation. Thereby, the investigator assume that use of pessaries in patients presenting a resolutive threatened preterm labor will also be effective.

To evaluate this hypothesis, the investigator designed a randomized prospective single-center open clinical trial comparing pessary associated with standard care (1st group) versus standard care only (2nd group) in patients experiencing an episode of resolutive threatened preterm labor.

Condition or Disease Intervention/Treatment Phase
  • Device: Silicone pessary
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
154 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
PREMAPESSAIRE: Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor: a Prospective, Randomized Monocentric Clinical Trial
Actual Study Start Date :
Dec 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pessary

Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)

Device: Silicone pessary
Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)

No Intervention: Control

Standard care only, No silicone pessary will be placed in the vagina.

Outcome Measures

Primary Outcome Measures

  1. Number of spontaneous delivery [37 weeks of gestation]

    Comparison of the number of spontaneous delivery before 37 completed weeks of gestation for pregnant women after resolutive threatened preterm labour between 20 and 34 weeks of gestation between the 2 groups of the study.

Secondary Outcome Measures

  1. Number of spontaneous delivery [34 weeks of gestation]

    Comparison of the number of spontaneous delivery before 34 completed weeks of gestation for pregnant women after resolutive threatened preterm labour between 20 and 34 weeks of gestation between the 2 groups of the study.

  2. Number of spontaneous delivery [28 weeks of gestation]

    Comparison of the number of spontaneous delivery before 28 completed weeks of gestation for pregnant women after resolutive threatened preterm labour between 20 and 34 weeks of gestation between the 2 groups of the study.

  3. Number of admission for preterm labor [from date of randomization until the date of the delivery]

    Comparison of the number of admission for preterm labor from date of randomization until the date of the delivery between the 2 groups.

  4. Number of fetal-neonatal death [at delivery]

    Number of fetal-neonatal death at delivery

  5. Number of birth death [From date of delivery until 6 weeks after the date of term]

    Number of birth death at delivery until 6 weeks after the date of term

  6. Number of patients with neonatal morbidity [From date of delivery until 6 weeks after the date of term]

    Number of patient with neonatal morbidity at delivery until 6 weeks after the date of term

  7. Number of patients with increase of vaginal discharge [from date of randomization until the date of the delivery]

    Comparison of the number of patients with increase of vaginal discharge from date of randomization until the date of the delivery between the 2 groups of the study.

  8. Number of patients with spontaneous pessary ejection [from date of randomization until the date of the delivery]

    Comparison of the number of patients with pessary ejection from date of randomization until the date of the delivery between the 2 groups of the study.

  9. Number of patients with discomfort [from date of randomization until the date of the delivery]

    Comparison of the number of patients with discomfort from date of randomization until the date of the delivery between the 2 groups of the study. The discomfort is measure by a standardized questionnaire.

  10. number of day between resolutive threatened preterm labor and delivery [At delivery]

    Comparison of number of day between the two groups of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Minimal age of 18 years

  • Informed consent

  • Confirmation of dating of pregnancy by first trimester echography.

  • Episode of threatened preterm labour

  • Singleton between 24 and 34 weeks of gestation

  • Cervical length ≤20mm in cervimetry

  • Pulmonary maturation completed

  • ≤6 contractions by hour after 24 hours of tocolysis.

Exclusion Criteria:
  • Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)

  • Spontaneous rupture of membranes at the time of randomization

  • Cervical cerclage in situ

  • Uterus malformations

  • Antecedent of conisation

  • Active vaginal bleeding, placenta previa

  • Intra-amniotic infection

  • Hydramnios

  • Maternal chronic pathology (hypertension, diabetes)

  • Anomaly of breathing foetal rate

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chu Saint-Etienne Saint-Etienne France 42055

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

Investigators

  • Principal Investigator: Céline CHAULEUR, PhD, CHU SAINT-ETIENNE

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT02484820
Other Study ID Numbers:
  • 1508059
  • 2015-A00672-47
First Posted:
Jun 30, 2015
Last Update Posted:
Apr 29, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 29, 2021